DSGN NASDAQ
Design Therapeutics, Inc.
1W: -24.3%
1M: -17.6%
3M: +8.9%
YTD: +21.0%
1Y: +200.0%
3Y: +75.3%
5Y: -52.1%
$10.97
-0.04 (-0.36%)
Weekly Expected Move ±16.2%
$10
$12
$14
$17
$19
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.30
Neutral
4 bullish
0 neutral
2 bearish
Articles (7d)
6
Daily Sentiment (7 Days)
Articles (23)
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May
Nasdaq Down 200 Points; Brady Earnings Top Views
At a glance: stocks gapping up premarket
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
Analysts Set Design Therapeutics, Inc. (NASDAQ:DSGN) PT at $15.20
Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings
Design Therapeutics, Inc. (NASDAQ:DSGN) Receives $15.25 Average PT from Brokerages
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% on Analyst Upgrade
Design Therapeutics GAAP EPS of -$0.27 beats by $0.10
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
DLD Asset Management LP Buys New Position in Design Therapeutics, Inc. $DSGN
Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s Why
Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00
Design Therapeutics (NASDAQ:DSGN) Trading Down 4.5% – Here’s Why
Design Therapeutics to Participate in Upcoming Investor Conferences